2006 Index

Nov

Coverage of 57th Annual Meeting of the American Association for the Study of Liver Disease

Treatment Extension to 72 Weeks of PegIntron plus Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow Responders with

Genotype 1 11/03/06

Risk Factors for Relapse in Patients with High Viral Load and Genotype 3 Hepatitis C in the WIN-R Trial  11/03/06

Pegasys plus Ribavirin for 16 versus 24 Weeks in Patients with HCV

 Genotype 2  11/03/06

Risk Factors for Relapse in Patients with High Viral Load and

 Genotype 3 Hepatitis C in the WIN-R Trial  11/03/06

Treatment Extension to 72 Weeks of PegIntron plus Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow Responders with

 Genotype 1  11/03/06

AUG

Distribution of Hepatitis C Virus Genotypes and Viral Load Levels in the U.S.
 

24-Week vs 48-Week Treatment with Pegasys Plus Ribavirin in HCV Genotype 1 Patient

JULY

Hepatic Steatosis Is Associated with Fibrosis, Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection in HIV-Seropositive Patients: Steatosis was present in 69% of patients -

JUNE

Largest U.S. Hepatitis C Trial Provides Insight Into Optimizing Treatment For Patients

Differences in Outcomes of Treatment with PegIntron Plus Fixed-dose or Weight-based Ribavirin Based on Genotype and Viral Load in HCV Genotypes 2 and 3 in The WIN-R Trial -

3 New Combination Therapies

New Phase 2 Studies of HCV Protease Inhibitor VX-950 Will Evaluate SVR Rates in Patients with HCV Genotype 1

Abstract T1814 – A randomized trial comparing Short Course versus Standard Treatment with non-pegylated interferon α and ribavirin in patients with Chronic Hepatitis C Genotype 3 Virus Infection.

Hepatic Iron, Liver Steatosis and HCV Genotypes in Patients with Chronic Hepatitis C -

Hispanic Patients with Genotype 2 or 3 Chronic Hepatitis C have Lower Rates of Sustained Virologic Response to Treatment with Pegylated Interferon and Ribavirin.

 5/23/06

Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin in the Retreatment   of Interferon/Ribavirin Nonresponders

Comparison of 48 vs 72 Weeks of Treatment with Peginterferon Alfa-2a plus Ribavirin in Patients with HCV Genotype 1

Factors That Predict a Rapid Virological Response at Week 4 and a Sustained Virological Response at Week 24

Blacks with HCV Genotype 1 (but Not Genotypes 2 or 3) Have a Lower SVR Rate Than Non-Blacks That Is Not Related to Dose Reductions of Interferon and Ribavirin

24 Weeks Treatment with Peginterferon Alfa-2b (PegIntron) plus Ribavirin Is Efficacious in Patients with Chronic HCV Genotype 1 and Low Pretreatment HCV RNA Levels

Interim Results of Studies of Albuferon plus Ribavirin in Nonresponders and in Treatment-naïve Patients with HCV Genotype 1 - 3/17/06

Pilot Study of Interferon-alfa+Ribavirin+Interleukin-2 for Treatment of Hepatitis C Virus Genotype 1 Patients with Severe Liver Disease Hepatitis -

Treatment of Genotype 1 Chronic Hepatitis C: Increased Sustained Virological Response with High-dose RBV and Epoetin

Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study

Short-term Treatment Duration for HCV Genotypes 2 and 3 Patients

Small Study Shows HCV RNA Levels Undetectable in 12 of 12 HCV Genotype 1 Patients after 4 Weeks of Treatment with Experimental HCV Drug VX 950 Plus Pegasys and Ribavirin - 2/10/06

Valopicitabine Dosed in Combination with Pegylated Interferon Alfa-2a (Pegasys) Leads to Rapid Virologic Response in 93 percent of Genotype 1 Hepatitis C Patients - 1/10/06

For more information visit HIV&Hepatitis Site

http://www.hivandhepatitis.com/hep_c/hepc_news_genotype.html#five